Muhammad Bilal Abid shared on LinkedIn:
“Screening alert
We are seeing younger and younger patients with incurable Colon Cancer. The purple bar shows how screening colonoscopy performs overall. If you’re at a higher than average risk, family Hx, start at 40 I did mine. Standard, average risk, please go for ScopeAt45.
It’s actually not that hard. Thanks, Dr Seifeldin Hakim, for taking me through my first smoothly.”
Dr. Abid shares valuable insights on his LinkedIn profile, covering a wide range of topics including cancer therapeutics, the latest developments in clinical trials, and the regulatory aspects of oncology drug development. His posts highlight cutting-edge research and clinical advances in the field of hematology and oncology, as well as the role of cellular therapies in transforming cancer treatment.
